Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.40
-0.0150-0.62%
Volume:1.84M
Turnover:4.43M
Market Cap:625.65M
PE:-7.28
High:2.45
Open:2.41
Low:2.38
Close:2.41
Loading ...

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

GlobeNewswire
·
Yesterday

Akebia Therapeutics Initiated at Outperform by Leerink Partners

Dow Jones
·
28 Apr

Leerink Partners Initiates Coverage on Akebia Therapeutics With Outperform Rating, $7 Price Target

MT Newswires Live
·
28 Apr

Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock

Zacks
·
10 Apr

US High Growth Tech Stocks to Watch in 2023

Simply Wall St.
·
09 Apr

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
04 Apr

Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment

MT Newswires Live
·
03 Apr

BRIEF-Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months

Reuters
·
03 Apr

Akebia announces CHMP positive opinion for XOANACYL

TIPRANKS
·
03 Apr

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for Xoanacyl®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

THOMSON REUTERS
·
03 Apr

Akebia Therapeutics: Ec Will Review Chmp Recommendation, Final Decision Expected in About Two Months

THOMSON REUTERS
·
03 Apr

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

GlobeNewswire
·
03 Apr

Akebia Therapeutics Initiated at Buy by Jefferies

Dow Jones
·
01 Apr

Jefferies Initiates Akebia Therapeutics at Buy With $6 Price Target

MT Newswires Live
·
01 Apr

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

GlobeNewswire
·
25 Mar

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Zacks
·
22 Mar

Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?

Insider Monkey
·
21 Mar

BUZZ-U.S. STOCKS ON THE MOVE-KKR, Micron Technology, Eli Lilly

Reuters
·
20 Mar

Akebia Therapeutics Down Over 27%, on Pace for Largest Percent Decrease Since February 2023 -- Data Talk

Dow Jones
·
20 Mar

Stock Track | Akebia Therapeutics Plummets 31% Following Deeply Discounted $50 Million Stock Offering

Stock Track
·
20 Mar